Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration

NCT00056823 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00056823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration
Lead sponsor
Genentech, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2003
Completion date
December 31, 2005
Enrollment
168
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

age-related maculopathy